Park Sung-In, Felipe Claudia R, Pinheiro-Machado Paula G, Garcia Riberto, Fernandes Fernanda B, Casarini Dulce E, Tedesco-Silva Helio, Medina-Pestana Jose O
Nephrology Division, Hospital do Rim e Hipertensão, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Fundam Clin Pharmacol. 2009 Feb;23(1):137-45. doi: 10.1111/j.1472-8206.2008.00644.x.
This study was conducted to evaluate time-dependent pharmacokinetic changes and drug interactions over the first 6 months after transplantation in kidney transplant recipients receiving tacrolimus (TAC), prednisone (PRED) and mycophenolate mofetil (MMF) or sirolimus (SRL). Pharmacokinetic assessments were carried out at day 7 and months 1, 3, and 6 in kidney transplant recipients receiving TAC plus PRED with either MMF (2 g/day, n = 13) or SRL (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day, n = 12). There were no differences in the main demographic characteristics or in mean PRED doses during the first 6 months after transplant. From day 7 to month 6, there was a 65% increase in TAC dose corrected exposure (dose corrected area under the curve; AUC) in patients receiving MMF (P = 0.005) and a 59% increase in TAC dose corrected exposure in patients receiving SRL (P = 0.008). From day 7 to month 6, there was a 72% increase in mycophenolate dose corrected exposure (P = 0.001) and a 65% increase in SRL dose corrected exposure (P = 0.008). TAC dose corrected exposure was 23% lower in patients receiving SRL compared with MMF (P = 0.012) on average over the study period. PRED dose reduction was associated with increase in TAC (in patients receiving SRL, P = 0.040) and mycophenolic acid (MPA) (P = 0.070) drug exposures. Tercile distribution of TAC drug exposure showed a positive correlation with mean SRL exposures (P = 0.016). Conversely, tercile distribution of SRL drug exposure showed a positive correlation with mean TAC exposures (P = 0.004). Time-dependent increases in TAC, MPA and SRL drug exposures occur up to 6 months after transplantation. Drug-to-drug interactions indicate that intense therapeutic drug monitoring is required to avoid under- or over-immunosuppression.
本研究旨在评估接受他克莫司(TAC)、泼尼松(PRED)和霉酚酸酯(MMF)或西罗莫司(SRL)的肾移植受者移植后前6个月内的时间依赖性药代动力学变化及药物相互作用。对接受TAC加PRED联合MMF(2 g/天,n = 13)或SRL(负荷剂量15 mg,7天内每日5 mg,之后每日2 mg,n = 12)的肾移植受者在第7天、1个月、3个月和6个月时进行药代动力学评估。移植后前6个月,主要人口统计学特征或平均PRED剂量无差异。从第7天到第6个月,接受MMF的患者TAC剂量校正暴露量(剂量校正曲线下面积;AUC)增加了65%(P = 0.005),接受SRL的患者TAC剂量校正暴露量增加了59%(P = 0.008)。从第7天到第6个月,霉酚酸剂量校正暴露量增加了72%(P = 0.001),SRL剂量校正暴露量增加了65%(P = 0.008)。在研究期间,接受SRL的患者TAC剂量校正暴露量平均比接受MMF的患者低23%(P = 0.012)。PRED剂量减少与TAC(接受SRL的患者中,P = 0.040)和霉酚酸(MPA)(P = 0.070)药物暴露增加相关。TAC药物暴露的三分位数分布与平均SRL暴露呈正相关(P = 0.016)。相反,SRL药物暴露的三分位数分布与平均TAC暴露呈正相关(P = 0.004)。移植后长达6个月,TAC、MPA和SRL药物暴露呈时间依赖性增加。药物间相互作用表明,需要进行强化治疗药物监测以避免免疫抑制不足或过度。